Elizabeth Fraley, CEO of Kinder Ready Launches Proven Reading Strategies to Boost Early Literacy for Young Learners.

June 21, 2025 3:50 PM

Elizabeth Fraley Kinder Ready, a leading provider of early childhood education in Los Angeles, has launched proven reading strategies to boost early literacy for young learners. With a focus on making reading engaging and enjoyable, these strategies are designed to help children develop strong literacy skills in preparation for kindergarten. By integrating fun, creativity, and research-backed methods, Elizabeth Fraley Kinder Ready ensures that...

Read more

Enviro Tech Chemical Services, Inc., an Arxada Company Files Patent Infringement Claim Against Clean Chemistry, Inc.

June 19, 2025 9:00 AM

Enviro Tech Chemical Services, Inc. ("Enviro Tech"), an Arxada company, announces that it has filed a claim of patent infringement against Clean Chemistry, Inc. ("Clean Chemistry"). The claim pertains to US Patent Nos. 8,546,449; 9,363,997; 9,730,443; and 9,737,072.Enviro Tech's patents cover alternative methods for generating peracetic acid (PAA) in-situ. These novel chemistries were developed specifically for our customers in the food,...

Read more

Moolec Science Secures Core U.S. Patent for Piggy Sooy(TM), Soybean Expressing Up to 30% of Animal Protein

June 18, 2025 7:00 AM

Moolec Science Limited a wholly-owned subsidiary of Moolec Science SA (NASDAQ:MLEC; "The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its proprietary groundbreaking Piggy Sooy™ technology - soybean plant engineered to express high levels of...

Read more

Year-End Report 2024/2025

June 18, 2025 2:20 AM

Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Positive development in the USA continuesSEK tQ424/25Q423/24May-April 24/25May-April 23/24Net sales2,3321,8998,6197,290Operating profit (loss)-20,341-41,490-85,839-126,845Profit (loss) for the period-20,766-39,532-87,624-124,823Earnings per share after dilution-0.21-0.47-0.95-2.14Number of shares at the end of the period97,786,38484,055,56092,569,24884,055,560Cash and cash equivalents...

Read more

Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals

June 17, 2025 11:58 PM

Lobe Sciences Ltd., (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) a leading biopharmaceutical company focused on breakthrough treatments for rare diseases, is advancing the development of its novel compound, Conjugated Psilocin™, following the April 14, 2025 spinout of the compound to the newly created Delaware corporation Cynaptec Pharmaceuticals, Inc. and signing of a key US$6 million investment non-brokered private placement agreement for preferred...

Read more

American Academy of Stem Cell Physicians Fall Conference in Miami October 3-5 , 2025!

June 17, 2025 10:43 AM

A highly anticipated and sought after AASCP meeting is back by popular demand slated for the fall of 2025. We are excited to invite you to one of the most dynamic events in the field of Regenrative Medicine! The Regenerative Medicine Fall Conference of 2025 will be taking place October 3-5 in Miami , Florida.Whether you are a season expert or just starting to explore the field, this conference offers all the knowledge, resources and networking...

Read more

NAYA Therapeutics Expands its Hepatocellular Carcinoma (HCC) Pipeline With First-in-Class GPC3-Targeted Astatine-211 Alpha Radioimmunotherapy

June 17, 2025 9:15 AM

NAYA Therapeutics, a clinical-stage biopharmaceutical company dedicated to pioneering the next generation of cancer immunotherapies, today announced that it is expanding its comprehensive hepatocellular carcinoma (HCC) pipeline with the addition of NY-700, a first-in-class GPC3-targeted Astatine-211 (211At) alpha radioimmunotherapy aiming to address residual disease, micro-metastasis, and post-immunotherapy failures. NAYA's HCC franchise also...

Read more

Drs. Lee Harrison and Alex Sundermann Join Next Gen Diagnostics Advisory Team to Advance Hospital-Based Infection Prevention

June 17, 2025 9:00 AM

Next Gen Diagnostics (NGD) today announced that Dr. Lee Harrison, Professor of Epidemiology and Director of the Center for Genomic Epidemiology at the University of Pittsburgh (Pitt), has agreed to chair NGD's Infection Prevention Advisory Board, and that Dr. Alex Sundermann, Assistant Professor of Epidemiology at Pitt and a widely recognized expert in genomic outbreak detection, has accepted a role as NGD's Lead Consultant for Infection...

Read more

Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors

June 17, 2025 8:01 AM

Tharimmune, Inc. (NASDAQ:THAR), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology, today announced significant appointments to its executive leadership and board of directors, reinforcing its commitment to advancing its pipeline and strategic initiatives. The Company is advancing its lead candidate TH104 specifically designed through a buccal film formulation to deliver an...

Read more

Aspira Women's Health Partners with Dorsata to Offer Access to 300+ Women's Health Practices, 1.5 Million + New Patients

June 17, 2025 7:00 AM

Aspira Women's Health Inc. a bio-analytical-based women's health company focused on gynecologic disease diagnostics, and Dorsata, a leading clinical decision-support and provider workflow platform for women's health, announced today the official launch of a new adnexal mass clinical decision support module in partnership with Dorsata, a leading women's health electronic health record software solutions company.Dorsata's platform is currently...

Read more

Moolec Science Announces Successful Closing of Business Combination, Expanding Across Life Sciences and Food-Tech

June 17, 2025 7:00 AM

Moolec Science SA (NASDAQ:MLEC) ("The Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced the successful closing of its previously announced strategic business combination (the "Business Combination") with Bioceres Group Limited ("Bioceres Group"), Gentle Technologies Corp ("Gentle Tech"), and Nutrecon LLC ("Nutrecon"). With the closing, Moolec emerges...

Read more

Alligator Receives Positive Scientific Advice from EMA on Phase 3 Trial of Mitazalimab

June 17, 2025 3:00 AM

Alligator Bioscience (STO:ATORX) - Lund, Sweden, 17 June 2025 - Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the European Medicines Agency (EMA) has provided positive scientific advice supporting the overall design of the planned Phase 3 study of mitazalimab in metastatic pancreatic cancer.The advice confirms that the proposed Phase 3 study...

Read more

uBriGene Launches Clinical iPSC Banks to Accelerate Regenerative Medicine and Cell Therapy Development

June 16, 2025 7:00 AM

uBriGene Biosciences, a leading cell and gene therapy CDMO, is proud to announce the launch of its fully characterized, ready-to-use induced pluripotent stem cell (iPSC) banks. Developed using uBriGene's proprietary RNA-LNP reprogramming technology, these iPSC banks are now available to support research, translational development, and clinical applications worldwide.uBriGene's iPSC seed banks and master cell banks (MCBs) are generated in...

Read more

AbTherx and GPCR Therapeutics Announce a Strategic Collaboration to Discover Novel Antibody-based Therapeutics for GPCR Targets

June 16, 2025 6:00 AM

AbTherx, a biotechnology company with innovative technologies that enable therapeutic antibody discovery against challenging targets, today announced a research collaboration with GPCR Therapeutics, a clinical-stage biopharmaceutical company, to discover and develop therapeutic antibodies targeting G protein-coupled receptors (GPCRs) for one target, with the potential to expand to additional targets.AbTherx's antibody discovery platform is built...

Read more

Adolore BioTherapeutics Announces Publication Demonstrating Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain via the Intra-Articular Route in Mice

June 15, 2025 3:55 PM

Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain and neurological disorders, today announced the publication of its manuscript titled, "Biosafety and Efficacy of Kv7 Activating rdHSV-CA8* Analgesic Gene Therapy for Chronic Pain Via the Intra-Articular Route in Mice1," in the peer-reviewed journal, Molecular Therapy.Roy Clifford...

Read more

NeuroEM Therapeutics(R) Closes Initial Rounds in $5 Million Equity Raise to Commercialize Drug-free Alzheimer's Treatment

June 13, 2025 10:15 AM

NeuroEM Therapeutics®, an award-winning clinical-stage biotechnology research company pioneering the use of radio frequencies to reverse Alzheimer's disease, has closed initial rounds totaling $1.33 million of a $5 million equity raise with BlueLake.vc. The Series A round supports continued progress toward commercialization of NeuroEM's Transcranial Electromagnetic Treatment (TEMT-RF) to prevent and treat cognitive decline caused by aging or...

Read more

Alligator Bioscience Receives FDA Endorsement of Mitazalimab Phase 3 Dose for Pancreatic Cancer

June 13, 2025 3:10 AM

Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has provided feedback supporting the selection of the 900 µg/kg dose of its CD40 agonist mitazalimab for the planned Phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC).This positive regulatory feedback confirms Alligator's dose selection...

Read more

BioInvent Presents Promising Phase 2a Monotherapy Data for BI-1808 in CTCL at EHA 2025

June 12, 2025 3:55 AM

BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated positive data from the ongoing Phase 2a dose expansion study of BI-1808 monotherapy in cutaneous T-cell lymphoma (CTCL). The data will be presented in a poster at the European Hematology Association (EHA) 2025...

Read more

Faron Pharmaceuticals presents updated Phase II data from BEXMAB Study at EHA 2025

June 12, 2025 2:45 AM

Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Strong efficacy and survival outcomes with bexmarilimab in high-risk MDS support Phase III advancementMedian overall survival (mOS) of 13.4 months in r/r HR-MDS patients (n=32) treated with bexmarilimab + azacitidine; mOS of 9.3 months in TP53 mutated patients (n=13)ORR of 85% and cCR of 50% in patients with frontline MDS (n=20)Deep bone marrow responses demonstrated at all dose levels in frontline...

Read more

Hong Kong Hosts World's Largest ISSCR Stem Cell Gathering for the First Time

June 11, 2025 9:51 PM

Reputed to be a leading research and development (R&D) hub for medical sciences, Hong Kong hosts the world's largest and most significant gathering of stem cell research and regenerative medicine, the International Society of Stem Cell Research (ISSCR) 2025 Annual Meeting. The event is brought to Hong Kong for the first time, thanks to the joint effort of three local universities - The University of Hong Kong, The Chinese University of Hong Kong...

Read more